| SEPTEMBER 15, 2026 |
| Ownership | PE-backed · New Mountain Capital (prior owner); New Mountain Capital, Roivant Sciences, Sixth Street, Transformation Capital, Merck Global Health Innovation Fund +4 more |
| Capital raised | $83M |
| Headcount | 7,369 FTEs |
| Headquarters | San Francisco, California |
| Leadership | Kyle Armbrester, Chief Executive Officer |
| Sell-side advisor | J.P. Morgan |
| Deal team | Blaine MacDougald (KKR) James Paquette (KKR) David Lyon (Neuberger Berman) Nikhil Krishnan (Neuberger Berman) |
| Buy-side advisor | — |